Key facts
- This page summarizes Brian Bernick's Form 4 filing for TherapeuticsMD, Inc. (TXMD).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Dec 2022, 18:41.
Brian Bernick - 06 Dec 2022 Form 4 Insider Report for TherapeuticsMD, Inc. (TXMD)
- Reporting relationship
- Co-Chief Executive Officer
- Issuer ticker
- TXMD
- Reported as of
- 06 Dec 2022
- Net transaction value
- -$6,621
- SEC form
- 4
- Accepted by SEC
- 09 Dec 2022, 18:41:23 UTC
- Prior SEC filing
- 16 Sep 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian Bernick
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Brian Bernick filed Form 4 for TherapeuticsMD, Inc. (TXMD) on 09 Dec 2022.
Change
- Previous filing in this sequence was filed on 16 Sep 2022.
- Current net transaction value: -$6,621.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TXMD
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +3,167
- Change %
- +162%
- Price
- $0.000000
- Shares after
- 5,127
- Date
- 06 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
TXMD
transaction
Common Stock
Sale
- Transaction value
- $4,602
- Shares
- -935
- Change %
- -18%
- Price
- $4.92
- Shares after
- 4,192
- Date
- 06 Dec 2022
- Ownership
- Direct
- Footnotes
- F2, F3
TXMD
transaction
Common Stock
Sale
- Transaction value
- $2,020
- Shares
- -320
- Change %
- -7.6%
- Price
- $6.31
- Shares after
- 3,872
- Date
- 09 Dec 2022
- Ownership
- Direct
- Footnotes
- F2
TXMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 35,147
- Date
- 06 Dec 2022
- Ownership
- See Footnote
- Footnotes
- F4
TXMD
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 60
- Date
- 06 Dec 2022
- Ownership
- See Footnote
- Footnotes
- F5
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TXMD
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -3,167
- Change %
- -23%
- Price
- $0.000000
- Shares after
- 10,517
- Date
- 06 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,167
- Exercise price
- $0.000000
- Footnotes
- F1, F6
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).
Footnote F2
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
Footnote F4
The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
Footnote F5
The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.
Footnote F6
The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.